Summary of Recognized Revenue |
The Company has recognized revenue from its collaboration and license agreements as follows:
|
|
Year Ended December 31,
|
|
|
|
2018
|
|
|
2017
|
|
|
2016
|
|
|
|
(in thousands)
|
|
Collaboration revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Celgene Corporation (“Celgene”) (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognition of up-front payment
|
|
$
|
6,567
|
|
|
$
|
16,694
|
|
|
$
|
27,730
|
|
Research and development services
|
|
|
119
|
|
|
|
660
|
|
|
|
-
|
|
Milestones and contingent payments
|
|
|
10,000
|
|
|
|
27,252
|
|
|
|
26,271
|
|
Total
|
|
|
16,686
|
|
|
|
44,606
|
|
|
|
54,001
|
|
Merck Sharp & Dohme Corporation (“Merck”)—
related party:
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognition of up-front payment
|
|
|
6,985
|
|
|
|
-
|
|
|
|
|
|
Research and development services
|
|
|
1,541
|
|
|
|
-
|
|
|
|
|
|
Total
|
|
|
8,526
|
|
|
|
-
|
|
|
|
-
|
|
Merck KGaA, Darmstadt, Germany (operating in
the United States and Canada under the name
“EMD Serono”):
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognition of up-front payment
|
|
|
4,142
|
|
|
|
4,120
|
|
|
|
4,120
|
|
Research and development services
|
|
|
3,033
|
|
|
|
3,015
|
|
|
|
1,610
|
|
Total
|
|
|
7,175
|
|
|
|
7,135
|
|
|
|
5,730
|
|
Total collaboration revenue
|
|
$
|
32,387
|
|
|
$
|
51,741
|
|
|
$
|
59,731
|
|
Other revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
Celgene Corporation (1):
|
|
|
|
|
|
|
|
|
|
|
|
|
Development and manufacturing services and
clinical product supply
|
|
$
|
4,501
|
|
|
$
|
-
|
|
|
|
|
|
SutroVax—related party:
|
|
|
|
|
|
|
|
|
|
|
|
|
Supply and other
|
|
|
1,531
|
|
|
|
-
|
|
|
|
|
|
Total other revenue
|
|
$
|
6,032
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Total revenue
|
|
$
|
38,419
|
|
|
$
|
51,741
|
|
|
$
|
59,731
|
|
|
(1)
|
Includes $5.0 million of collaboration revenue and $3.9 million of other revenue from Celgene as related party revenue. Celgene was a related party through September 30, 2018 as it held more than 10% of our common stock for the periods presented until the closing of our IPO.
|
|